Contract development and manufacturing organizations (CDMOs) including Lonza, Thermo Fisher, and Samsung Biologics reported earnings exceeding expectations despite client funding challenges and tariffs. Thermo Fisher posted 3% year-over-year revenue growth and an 11% stock surge following strong Q2 results driven by life sciences and laboratory products segments. Danaher reported 4% revenue growth propelled by bioprocessing despite ongoing headwinds from China regulations and tariffs. These results reflect resilience in biotech services amid a cautious macroeconomic environment and underscore ongoing industry investment in innovation.